SummaryRMgm-47
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 9267031 |
MR4 number |
MRA-266 |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei NK65 |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | A.A. Sultan, V. Nussenzweig, V. Thathy, R. Menard |
Name Group/Department | Department of Pathology, Kaplan Cancer Center |
Name Institute | New York University Medical Center |
City | New York |
Country | USA |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-47 |
Principal name | TRAP(-); REP1; REP2 |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Not different from wild type |
Fertilization and ookinete | Not different from wild type |
Oocyst | Not different from wild type |
Sporozoite | Normal numbers of midgut sporozoites are formed. Sporozoites do not display gliding motility. Sporozoites are strongly affected in their capacity to invade salivary glands (the number of salivary gland–associated, sporozoites per infected mosquito was 34 times smaller than in wild type). Sporozoites are also affected in their infectivity to Sprague-Dawley rats (~10,000 times less infective than wild type sporozoites). |
Liver stage | Sporozoites are affected in their infectivity to Sprague-Dawley rats (~10,000 times less infective than wild type sporozoites). |
Additional remarks phenotype | Mutant/mutation Protein (function) The role of the different domains of the protein in motility and invasion has been analysed in mutant parasites expressing mutated forms of TRAP (see below). Phenotype Additional information In the same study mutants are described (INT1, INT2) that have been generated using a construct that integrates by single cross-over integration. The disadvantage of using such integration constructs is that the construct can be removed from the genome, thereby restoring the wild type genotype. One mutant has been deposited at MR4 (MRA-265) Adhesion of sporozoites of this mutant has been analysed in another study (Hegge et al., 2010, FASEB J; PMID: 20159960). Mutant sporozoites showed significant weaker adhesion on glass slides as compared to wild type parasites. Other mutants |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_1349800 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_1335900 | ||||||||||||||||||||||||
Gene product | thrombospondin-related anonymous protein | sporozoite surface protein 2 | ||||||||||||||||||||||||
Gene product: Alternative name | sporozoite surface protein 2; SSP2; SSP-2; TRAP | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | tgdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | The mutants have been generated using a construct that disrupt the trap gene by double cross-over integration (replacement vector). In the same study mutants are described (INT1, INT2) that have been generated using a construct that integrates by single cross-over integration. The disadvantage of using such integration constructs is that the construct can be removed from the genome, thereby restoring the wild type genotype. | ||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
Primer information: Primers used for amplification of the target sequences
| |||||||||||||||||||||||||
top of page |